Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 1, 2023

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

GlobeNewswire January 4, 2023

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 3, 2023

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

GlobeNewswire December 10, 2022

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2022

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 14, 2022

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

GlobeNewswire November 3, 2022

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results

GlobeNewswire October 27, 2022

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma

GlobeNewswire October 3, 2022

Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

GlobeNewswire September 27, 2022

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

GlobeNewswire September 23, 2022

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

GlobeNewswire August 2, 2022

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

GlobeNewswire July 14, 2022

Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

GlobeNewswire June 10, 2022

Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

GlobeNewswire June 10, 2022

Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

GlobeNewswire June 2, 2022